Activation of ERK and downstream targets have been identified in individual MF and post-MPN sAML patients (33), and likewise JAK2-dependent ERK activity has been shown to contribute to disease phenotypes in JAK2 V617F and MPL W515L expressing mice (112). Here, JAK2 is linked to myeloproliferative neoplasm.